

## Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call

PETALUMA, Calif., May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018, will be released after the U.S. markets close on June 13, 2018. The earnings release will be followed by a conference call at 1:30 p.m. PDT on June 13, 2018, to discuss fiscal fourth quarter and year-end results.

Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at <a href="https://edge.media-server.com/m6/p/ufhciggt">https://edge.media-server.com/m6/p/ufhciggt</a>.

A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 3495907. A webcast replay will be available on the site at <a href="http://ir.sonomapharma.com/events.cfm">http://ir.sonomapharma.com/events.cfm</a> for one year following the call.

## About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com

## Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

Bob Miller CFO (925) 787-6218



Source: Sonoma Pharmaceuticals. Inc.